Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions convey overall support and curiosity about the research, with examples like mentions of the 27% increase in negative tests and phrases like 'bold discoveries' and 'significantly reduce' reflecting a tone of optimism and importance. The tone and word choices suggest a recognition of the study's relevance in advancing treatments for methamphetamine use disorder.
Most discussions endorse the positive results and potential of the combined treatment, with many highlighting the significant reduction in methamphetamine use shown in the trial.
The posts demonstrate moderate interest, as they focus on sharing study outcomes and highlighting their importance, but lack detailed critical analysis or personal insights.
Participants reference specific data points such as increases in negative test results and mention the significance of treatment duration, indicating a moderate level of in-depth engagement.
The discussion emphasizes the potential impact of the treatment as a notable development in addiction medicine, suggesting it could influence future treatment protocols.
For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional reductions in MA use up to 12 weeks. Read the full study by Michael Li @uclaFM and colleagues here https://t.co/HfjGeR3MZa https://t.co/TklAsrINy6
ADAPT-2 trial: People with methamphetamine UD receiving treatment with naltrexone + bupropion XL showed a greater increase in their probability of testing negative for MA after 12-week vs. placebo (15.8%: P=0.006) https://t.co/KHANNOD36r
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Addiction - Wiley Online Library https://t.co/xgwxqQGekU
**Bold Discoveries in Battling Meth Use Disorder:** The latest ADAPT-2 trial shows that NTX + BUPN treatments significantly reduce methamphetamine use over 12 weeks compared to placebo.
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
This video provides quick summaries of our last 10 articles, focusing on electronic nicotine-delivery systems (e-cigarettes) in smoking cessation. Results indicate mixed effectiveness with a higher continuous abstinence…
This video provides a roundup of key scientific articles, including a study on electronic nicotine-delivery systems for smoking cessation. The trial compared e-cigarette users with a control group, revealing higher…
RT @AlyAdybBear: Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Ad…
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Addiction - Wiley Online Library https://t.co/xgwxqQGekU
A recent publication by CHIPTS very own CP Core Scientist Dr. Michael Li on the “Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial," was highlighted on @UCLAHealth news. Read here: https://t.co/37fQ98hPZD https://t.co/0T7qN2BTFW
ADAPT-2 trial: People with methamphetamine UD receiving treatment with naltrexone + bupropion XL showed a greater increase in their probability of testing negative for MA after 12-week vs. placebo (15.8%: P=0.006) https://t.co/KHANNOD36r
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
**Bold Discoveries in Battling Meth Use Disorder:** The latest ADAPT-2 trial shows that NTX + BUPN treatments significantly reduce methamphetamine use over 12 weeks compared to placebo.
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional reductions in MA use up to 12 weeks. Read the full study by Michael Li @uclaFM and colleagues here https://t.co/HfjGeR3MZa https://t.co/TklAsrINy6
New Post: Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial https://t.co/kT4oFspRf5